United States · 
Who invested in BlinkRx?
BlinkRx's investors include 1789 Capital, BoxGroup, 8VC, K Fund and Deerfield. 1789 Capital led its latest round.
2025
$140MSeries D$140MGrowth
United States · Growth startup
Who invested in BlinkRx
2 rounds we have observed, with the 5 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Follow BlinkRx and see its new rounds in your feed. Start following
Funding summaryUpdated 15 Nov 2026
$280Mraised across 2 rounds since 2024, from 4 sources
$140MSeries D$140MGrowth
- Latest round
- Growth, $140MFeb 2025
- Led by
- 1789 Capital
- Investors
- 5 (1 led)
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Series D, $140M Nov 2024
- Biggest round
- $140M Growth · Feb 2025
- Between rounds
- 3 months from the last two
The rounds
- Feb 2025
- Nov 2024
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about BlinkRx
How much has BlinkRx raised?
BlinkRx has raised $280M across 2 rounds since 2024.
When did BlinkRx last raise?
BlinkRx's most recent round was a Growth of $140M in Feb 2025, led by 1789 Capital.
What was BlinkRx's biggest round?
Its most recent round, $140M in Feb 2025, is also its largest on record.
Who backed BlinkRx first?
BlinkRx's first round on record, in Nov 2024, was backed by BoxGroup, 8VC and K Fund and 1 others.
What stage is BlinkRx at?
BlinkRx's latest named round is a Growth, in Feb 2025.
Where is BlinkRx based?
BlinkRx is based in the United States.
Who led BlinkRx's rounds?
1789 Capital led the Growth in 2025.
Companies like BlinkRx
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.